Advanced NanoTherapies Announces Breakthrough in Coronary Disease Treatment with SirPlux™ Duo

Santa Clara, Calif., October 26, 2024 – Advanced NanoTherapies (ANT), a leader in medical nanotechnology applications, has announced encouraging results from its initial human trials of the SirPlux™ Duo Drug-Coated Balloon (DCB). This groundbreaking treatment utilizes a combination of sirolimus and paclitaxel, specifically designed to tackle coronary de novo disease by maintaining vascular patency and preventing restenosis. Research sites for the study include Cecanot Hospital in Santo Domingo, Dominican Republic.

Gearing up for further research, ANT has confirmed plans to conduct the DYNAMIC DUO I early feasibility study in the United States. This study will assess the safety and efficacy of the innovative SirPlux™ Duo DCB. ANT’s drug delivery platform, leveraging cutting-edge nanoparticle technology, ensures sustained and potent drug delivery directly to affected coronary tissues without leaving behind permanent implants.

Dr. Bernardo Cortese, a prominent figure in cardiovascular medicine, remarked, "The SirPlux Duo DCB could redefine approaches to coronary disease treatment, presenting a leading-edge alternative to traditional invasive methods."

The DYNAMIC DUO I study is a prospective, multicenter, non-randomized trial that will enroll and treat patients with stable angina, unstable angina, or NSTEMI who have de novo coronary lesions with reference vessel diameters of 2 to 4 mm. The results of this study will be pivotal in determining the next steps for ANT's clinical programs, aiming for broader commercialization in the U.S. and global markets.